Xarelto Lawsuit Requests $4.35 Million Following Alleged Severe Bleeding Episode

April 29, 2016 – – BloodThinnerHelp.com discusses information from yet another Xarelto-related lawsuit filed against manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), as well as multiple other defendants. The plaintiff filing the lawsuit alleges that use of the new-generation blood-thinning drug caused him to suffer from an unexpected and severe bleeding event. His lawsuit was transferred to be consolidated with thousands of others in a move by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL 2592. Today, MDL 2592 involves over 2,800 complaints which all commonly allege the dangers of Xarelto. The cases are being overseen in Eastern Louisiana by Judge Eldon E. Fallon.

This lawsuit is especially notable as it involves 90-counts and requests a large monetary compensation: $4.35 million. The plaintiff alleges that defendants purposefully marketed Xarelto in misleading ways to display it as both safe and effective, while neglecting to properly address potential dangerous side effects which have been linked to its use. Other plaintiffs have also drawn attention to Xarelto marketing tactics, and have noted the use of celebrity endorsements and potentially misleading information.

This lawsuit plaintiff, however, addresses the fact that the drug’s manufacturers had likely been previously aware that their drug could cause serious bleeding risks for patients using it, and he offers supporting evidence for this case. The man noted, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”

Similar allegations surrounding Xarelto have been made through adverse event reports to the FDA, and additional controversies surrounding the FDA’s approval of the drug have recently spawned an investigation by European Regulators. Prior information has shown that Xarelto manufacturers spent over $11 million to promote the drug, and that their tactics brought in an estimated $582 million in revenue in the drug’s first year on the market alone. Xarelto was approved and released to market just 5 years ago, in 2011, and has since become the subject of more than 3,400 lawsuits from across America. Lawsuits concerning the drug have now been filed in Canada as well.

Attorney Joseph Osborne is working to help other patients who have used Xarelto and who feel that the drug has negatively impacted their health. He wants to ensure that all affected patients will be given an opportunity to fully investigate their legal rights in the matter, as they could be entitled to significant compensation. To help patients desiring to learn more about their legal options, Attorney Osborne is now offering free legal consultations for qualified parties.

To request additional information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009699